Caerus Investment Advisors LLC Buys Shares of 17,638 Exelixis, Inc. $EXEL

Caerus Investment Advisors LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,638 shares of the biotechnology company’s stock, valued at approximately $773,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Anchor Investment Management LLC grew its stake in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Activest Wealth Management purchased a new position in Exelixis in the fourth quarter valued at about $32,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Exelixis in the fourth quarter worth about $44,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in shares of Exelixis in the third quarter worth about $47,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity

In related news, EVP Dana Aftab sold 43,451 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president directly owned 594,741 shares in the company, valued at $29,945,209.35. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George Poste sold 60,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $45.71, for a total value of $2,742,600.00. Following the transaction, the director owned 118,832 shares in the company, valued at $5,431,810.72. This represents a 33.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EXEL. TD Cowen boosted their price target on Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. HC Wainwright boosted their price target on Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Stifel Nicolaus boosted their price target on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada cut their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a research report on Monday, March 2nd. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis presently has a consensus rating of “Hold” and a consensus target price of $47.35.

Exelixis Stock Performance

NASDAQ EXEL opened at $53.50 on Friday. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $53.93. The stock has a market capitalization of $13.45 billion, a PE ratio of 17.77, a P/E/G ratio of 1.52 and a beta of 0.41. The stock has a 50-day simple moving average of $47.80 and a 200 day simple moving average of $44.83.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. During the same quarter in the previous year, the firm earned $0.55 EPS. The firm’s revenue was up 10.0% compared to the same quarter last year. As a group, equities research analysts forecast that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.